Greenwich Lifesciences, Inc. (GLSI) — SEC Filings
Greenwich Lifesciences, Inc. (GLSI) — 16 SEC filings. Latest: 8-K (Dec 18, 2025). Includes 6 8-K, 6 10-Q, 2 DEF 14A.
View Greenwich Lifesciences, Inc. on SEC EDGAR
Overview
Greenwich Lifesciences, Inc. (GLSI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 18, 2025: Greenwich LifeSciences, Inc. filed an 8-K on December 18, 2025, reporting on a submission of matters to a vote of security holders. The filing does not contain specific details about the vote itself or any associated financial figures.
Sentiment Summary
Across 16 filings, the sentiment breakdown is: 2 bearish, 14 neutral. The dominant filing sentiment for Greenwich Lifesciences, Inc. is neutral.
Filing Type Overview
Greenwich Lifesciences, Inc. (GLSI) has filed 6 8-K, 6 10-Q, 2 DEF 14A, 2 10-K with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (16)
Risk Profile
Risk Assessment: Of GLSI's 16 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$11,435,485 |
| EPS | -$0.85 |
| Debt-to-Equity | N/A |
| Cash Position | $3,806,978 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Snehal Patel
- David B. McWilliams
- Snehal S. Patel
Industry Context
Greenwich LifeSciences operates in the highly competitive and capital-intensive biopharmaceutical industry. Success is contingent on the costly and lengthy process of drug discovery, development, clinical trials, and regulatory approval. Companies in this sector often rely heavily on external financing due to significant R&D expenditures and lack of immediate revenue generation.
Top Tags
10-Q (4) · financials (4) · corporate-governance (3) · pharmaceuticals (3) · shareholder-vote (2) · Biotechnology (2) · Oncology (2) · Clinical Trials (2) · Going Concern (2) · Equity Financing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $11.4M | Increased by 47.6% for the nine months ended September 30, 2025, compared to $7.7M in 2024. |
| Research and Development Expenses | $9.6M | Increased by 41.7% for the nine months ended September 30, 2025, from $6.8M in 2024. |
| Cash Balance | $3.8M | Decreased from $4.1M at December 31, 2024, indicating ongoing cash burn. |
| Net Proceeds from ATM Offerings | $6.3M | Raised during the nine months ended September 30, 2025, to fund operations. |
| Net Cash Used in Operating Activities | $6.7M | For the nine months ended September 30, 2025, highlighting significant operational cash burn. |
| Revenue | 0% | The company reported no revenue for the three and nine months ended September 30, 2025 and 2024. |
| Net Loss Per Share | $0.85 | For the nine months ended September 30, 2025, up from $0.60 in 2024. |
| Shares Outstanding | 13,794,577 | As of September 30, 2025, an increase from 13,152,729 shares at December 31, 2024, due to equity raises. |
| Annual Meeting Date | December 18, 2025 | Date stockholders will vote on proposals |
| Record Date | October 28, 2025 | Date for determining stockholders entitled to vote |
| Number of Directors to Elect | 5 | Key proposal for board composition |
| Shares of Common Stock Outstanding | 13,854,539 | Total shares eligible to vote as of Record Date |
| Shares for Quorum | 6,927,270 | Majority of outstanding shares required for a quorum |
| Fiscal Year End | December 31, 2025 | Period for which MaloneBailey LLP is appointed auditor |
| General and Administrative Expenses | $1,219,257 | Increased 75.1% for the six months ended June 30, 2025, from $696,219 in 2024. |
Frequently Asked Questions
What are the latest SEC filings for Greenwich Lifesciences, Inc. (GLSI)?
Greenwich Lifesciences, Inc. has 16 recent SEC filings from Feb 2024 to Dec 2025, including 6 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GLSI filings?
Across 16 filings, the sentiment breakdown is: 2 bearish, 14 neutral. The dominant sentiment is neutral.
Where can I find Greenwich Lifesciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Greenwich Lifesciences, Inc. (GLSI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Greenwich Lifesciences, Inc.?
Key financial highlights from Greenwich Lifesciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GLSI?
The investment thesis for GLSI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Greenwich Lifesciences, Inc.?
Key executives identified across Greenwich Lifesciences, Inc.'s filings include Snehal Patel, David B. McWilliams, Snehal S. Patel.
What are the main risk factors for Greenwich Lifesciences, Inc. stock?
Of GLSI's 16 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Greenwich Lifesciences, Inc.?
Forward guidance and predictions for Greenwich Lifesciences, Inc. are extracted from SEC filings as they are enriched.